Lexaria Bioscience (LEXX) has released an update.
Lexaria Bioscience has launched a new human pilot study to evaluate the oral administration of DehydraTECH-processed tirzepatide, a drug currently only available via injection and expected to generate substantial revenue. The study aims to assess the drug’s tolerability, blood absorption, and glucose control in volunteers and follows successful previous studies that showed improved outcomes with another diabetes medication processed with Lexaria’s DehydraTECH technology.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
